A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection

详细信息    查看全文

• 作者：Jia-Horng Kao ; Rong-Nan Chien ; Ting-Tsung Chang ; Cheng-Yuan Peng ; Tsung-Hui Hu ; Gin-Ho Lo ; Horng-Yuan Wang ; Jyh-Jou Chen ; Jenny C. Yang ; Steven J. Knox ; Lingling Han ; Hongmei Mo ; Anita Mathias ; Diana M. Brainard ; I-Shyan Sheen ; Yu-Chun Hsu ; Chi-Jen Chu and Wan-Long Chuang
• 刊名：Liver International
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：36
• 期：8
• 页码：1101-1107
• 全文大小：188K
• ISSN：1478-3231

文摘

In Taiwan, patients with chronic hepatitis C virus (HCV) infection are currently treated with pegylated interferon-alpha plus ribavirin, but interferon-based regimens can be poorly tolerated, especially by those with advanced liver disease and the elderly. Sofosbuvir, an oral nucleotide analogue inhibitor of HCV NS5B polymerase, is approved in Europe, the USA and Japan for treating chronic HCV infection. This phase 3b study examined the efficacy and safety of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 HCV infection ± compensated cirrhosis.